Completed PHASE1 INTERVENTIONAL NCT00100282

Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease

Single Dose Escalation Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease

Sponsor: PRAECIS Pharmaceuticals Inc.

Updated 6 times since 2017 Last updated: Sep 18, 2006 Started: May 31, 2003 Completion: Jun 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Alzheimer's Disease, this trial is completed. The trial is conducted by PRAECIS Pharmaceuticals Inc. and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2020 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Sep 2020 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PRAECIS Pharmaceuticals Inc.

Data source: PRAECIS Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Orange, United States
• Princeton, United States